Trial Profile
A multisite phase II clinical trial to evaluate the immunogenicity and safety of ALVAC-HIV vCP1452 alone and combined with MN rgp120
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Aug 2009
Price :
$35
*
At a glance
- Drugs HIV vaccine vCP1452 (Primary) ; MN-rgp120 HIV-1 vaccine
- Indications HIV infections
- Focus Adverse reactions; Pharmacodynamics
- 11 Aug 2009 Actual end date (1 Jul 2004) added as reported by ClinicalTrials.gov.
- 11 Aug 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 Sep 2008 Actual patient number (160) added as reported by CT.gov